{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:12:15Z","timestamp":1787879535566,"version":"build-2784847793"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01538-4","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:39:06Z","timestamp":1757590746000},"page":"3071-3088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice"],"prefix":"10.1007","volume":"15","author":[{"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"1","key":"1538_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12967-020-02316-w","volume":"18","author":"AM Vicente","year":"2020","unstructured":"Vicente AM, Ballensiefen W, J\u00f6nsson JI. How personalised medicine will transform healthcare by 2030: the ICPerMed vision. J Transl Med. 2020;18(1):180.","journal-title":"J Transl Med"},{"issue":"1","key":"1538_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2340\/00015555-1183","volume":"92","author":"K Douroudis","year":"2012","unstructured":"Douroudis K, Kingo K, Traks T, Reimann E, Raud K, R\u00e4tsep R, et al. Polymorphisms in the ATG16L1 gene are associated with psoriasis vulgaris. Acta Derm Venereol. 2012;92(1):85\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1538_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1365-2133.2006.07731.x","volume":"156","author":"K Kingo","year":"2007","unstructured":"Kingo K, M\u00f6ssner R, K\u00f5ks S, R\u00e4tsep R, Kr\u00fcger U, Vasar E, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156(4):646\u201352.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1538_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.gene.6364046","volume":"5","author":"K Kingo","year":"2004","unstructured":"Kingo K, K\u00f5ks S, Nikopensius T, Silm H, Vasar E. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 2004;5(2):117\u201321.","journal-title":"Genes Immun"},{"issue":"8","key":"1538_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15152","volume":"33","author":"B Butr\u00f3n-Bris","year":"2024","unstructured":"Butr\u00f3n-Bris B, Llamas-Velasco M, Ovejero-Benito MC, Santos-Juanes J, Mart\u00ednez-L\u00f3pez A, Ruiz-Villaverde R, et al. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice. Exp Dermatol. 2024;33(8):e15152.","journal-title":"Exp Dermatol"},{"issue":"2","key":"1538_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/jdv.19567","volume":"38","author":"R Sommer","year":"2024","unstructured":"Sommer R, Mrowietz U, Gaarn Du Jardin K, Kasujee I, Martini E, Daud\u00e9n E, et al. Implementing well-being in the management of psoriasis: An expert recommendation. J Eur Acad Dermatol Venereol. 2024;38(2):302\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1538_CR7","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s12325-022-02124-2","volume":"39","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Edson-Heredia E, Zhu B, Burge R, Bell S, Crowley JJ, et al. Treatment goals for psoriasis as measured by patient benefit index: results of a National Psoriasis Foundation survey. Adv Ther. 2022;39(6):2657\u201367.","journal-title":"Adv Ther"},{"key":"1538_CR8","doi-asserted-by":"crossref","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u2013881.e1\u201330.","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"1538_CR9","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.583","volume":"102","author":"N Zozaya","year":"2022","unstructured":"Zozaya N, Villoro R, Abdalla F, Alfonso Zamora S, Balea Filgueiras J, Carrascosa Carrillo JM, et al. Unmet needs in the management of moderate-to-severe psoriasis in Spain: a multidimensional evaluation. Acta Derm Venereol. 2022;102:adv00678.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1538_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.36849\/JDD.6589","volume":"21","author":"C Porter","year":"2022","unstructured":"Porter C, Woods A, Mendelow M, Purvis C, Feldman S. Unmet needs in psoriasis patients. J Drugs Dermatol. 2022;21(8):839\u201344.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"1538_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","volume":"149","author":"H Yeung","year":"2013","unstructured":"Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173\u20139.","journal-title":"JAMA Dermatol"},{"key":"1538_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"key":"1538_CR13","unstructured":"National Psoriasis Foundation. Psoriasis: Symptoms, Causes, Images and Treatment [Internet]. https:\/\/www.psoriasis.org\/about-psoriasis?utm_source=redirect&utm_medium=link&utm_campaign=redirect. Accessed 11 Mar 2025."},{"issue":"12","key":"1538_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537\u201341.","journal-title":"Arch Dermatol"},{"issue":"25","key":"1538_CR15","first-page":"02238","volume":"S0190\u20139622","author":"BE Strober","year":"2025","unstructured":"Strober BE, Blauvelt A, van de Kerkhof PC, Gonz\u00e1lez-Cantero \u00c1, El-Kalioby M, Gonzalez C, et al. International Psoriasis Council psoriasis disease severity reclassification: update on validity, acceptance, and implementation. J Am Acad Dermatol. 2025;S0190\u20139622(25):02238\u201348.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1538_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0022-3999(00)00210-5","volume":"50","author":"HL Richards","year":"2001","unstructured":"Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50(1):11\u20135.","journal-title":"J Psychosom Res"},{"issue":"3","key":"1538_CR17","first-page":"280","volume":"137","author":"G Krueger","year":"2001","unstructured":"Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280\u20134.","journal-title":"Arch Dermatol"},{"issue":"12","key":"1538_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003\u20132011. PLoS ONE. 2012;7(12):e52935.","journal-title":"PLoS ONE"},{"issue":"3 Pt 1","key":"1538_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1538_CR20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011. JAMA Dermatol. 2013;149(10):1180\u20135.","journal-title":"JAMA Dermatol"},{"issue":"2S","key":"1538_CR21","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.12788\/j.sder.2018.012","volume":"37","author":"JJ Wu","year":"2018","unstructured":"Wu JJ, Armstrong AW, Gordon KB, Menter MA. Practical strategies for optimizing management of psoriasis. Semin Cutan Med Surg. 2018;37(2S):S52\u20135.","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"1538_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","volume":"7","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2016;7(1):97\u2013109.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1538_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/jdv.20546","volume":"39","author":"R Gyulai","year":"2025","unstructured":"Gyulai R. Closing the gap between possibilities and reality in psoriasis management. J Eur Acad Dermatol Venereol. 2025;39(3):449\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1538_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1538_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ad.2014.04.004","volume":"105","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Notario J. Drug survival in biologic therapy. Do we know what it means? Can we calculate it? Actas Dermosifiliogr. 2014;105(8):729\u201333.","journal-title":"Actas Dermosifiliogr"},{"issue":"19","key":"1538_CR26","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"3","key":"1538_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","volume":"42","author":"AM Wride","year":"2024","unstructured":"Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM. Biologics for psoriasis. Dermatol Clin. 2024;42(3):339\u201355.","journal-title":"Dermatol Clin"},{"issue":"10","key":"1538_CR28","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.351","volume":"101","author":"CW Schwarz","year":"2021","unstructured":"Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol. 2021;101(10):adv00579.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1538_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","volume":"180","author":"RB Warren","year":"2019","unstructured":"Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069\u201376.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1538_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15378","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Susca S, Megna M, Siliquini N, Quaglino P, Ortoncelli M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35(5):e15378.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1538_CR31","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15231","volume":"35","author":"E Del Alc\u00e1zar","year":"2022","unstructured":"Del Alc\u00e1zar E, L\u00f3pez-Ferrer A, Mart\u00ednez-Dom\u00e9nech \u00c1, Ruiz-Villaverde R, Llamas-Velasco MDM, Rocamora V, et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(2):e15231.","journal-title":"Dermatol Ther"},{"key":"1538_CR32","first-page":"AB220","volume":"54","author":"B Strober","year":"2006","unstructured":"Strober B, Gottlieb A, Leonardi C, Papp KI. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J Am Acad Dermatol. 2006;54:AB220.","journal-title":"J Am Acad Dermatol"},{"issue":"3 (Suppl 2)","key":"1538_CR33","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.jaad.2005.11.1088","volume":"54","author":"K Gordon","year":"2006","unstructured":"Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 (Suppl 2)):S101-111.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1538_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1538_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13(5):e0195123.","journal-title":"PLoS ONE"},{"issue":"3","key":"1538_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","volume":"63","author":"A Menter","year":"2010","unstructured":"Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1538_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","volume":"63","author":"M Lebwohl","year":"2010","unstructured":"Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1538_CR38","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14712598.2019.1622678","volume":"19","author":"M Megna","year":"2019","unstructured":"Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855\u201361.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1538_CR39","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1111\/jdv.17003","volume":"35","author":"K Hansel","year":"2021","unstructured":"Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35(3):e169\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1538_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14202","volume":"33","author":"E Herrera-Acosta","year":"2020","unstructured":"Herrera-Acosta E, Garriga-Martina GG, Su\u00e1rez-P\u00e9rez JA, Mart\u00ednez-Garc\u00eda E, Herrera-Ceballos E. Ixekizumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice. Dermatol Ther. 2020;33(6):e14202.","journal-title":"Dermatol Ther"},{"issue":"12","key":"1538_CR41","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/1346-8138.16128","volume":"48","author":"S Gerdes","year":"2021","unstructured":"Gerdes S, Br\u00e4u B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854\u201362.","journal-title":"J Dermatol"},{"issue":"3","key":"1538_CR42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000513398","volume":"237","author":"F Assan","year":"2021","unstructured":"Assan F, Tubach F, Arlegui H, Viguier M, Beylot-Barry M, Dupuy A, et al. First-line biologic therapy and obesity in moderate-to-severe psoriasis: results from the prospective multicenter cohort Psobioteq. Dermatology. 2021;237(3):338\u201346.","journal-title":"Dermatology"},{"issue":"2","key":"1538_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/JD9.0000000000000155","volume":"4","author":"C Xu","year":"2021","unstructured":"Xu C, Ji J, Su T, Wang HW, Su ZL. The association of psoriasis and obesity: focusing on IL-17A-related immunological mechanisms. Int J Dermatol Venereol. 2021;4(2):116.","journal-title":"Int J Dermatol Venereol"},{"issue":"3","key":"1538_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"JM Carrascosa","year":"2022","unstructured":"Carrascosa JM, Puig L, Belinch\u00f3n Romero I, Salgado-Boquete L, Del Alc\u00e1zar E, Andr\u00e9s Lencina JJ, et al. Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the treatment of psoriasis with biologic therapy. Part 1. Concepts and general management of psoriasis with biologic therapy. Actas Dermosifiliogr. 2022;113(3):261\u201377.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"1538_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1684\/ejd.2020.3945","volume":"30","author":"T Torres","year":"2020","unstructured":"Torres T, Tavares Bello R, Paiva Lopes MJ, Menezes Brand\u00e3o F, Ferreira A, Ferreira P, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy. Eur J Dermatol. 2020;30(6):645\u201354.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"1538_CR46","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.20568","volume":"185","author":"K Reich","year":"2021","unstructured":"Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146\u201359.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1538_CR47","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(6):1149\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1538_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Thaci","year":"2021","unstructured":"Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323\u201334.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1538_CR49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","volume":"10","author":"MJ McGeachy","year":"2009","unstructured":"McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314\u201324.","journal-title":"Nat Immunol"},{"issue":"6","key":"1538_CR50","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jaad.2024.06.103","volume":"91","author":"C Pfau","year":"2024","unstructured":"Pfau C, Lovell KK, Feldman SR. Extrapolating the speed of psoriasis clearance: a comparative analysis of biologic agents in clinical trials. J Am Acad Dermatol. 2024;91(6):1223\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1538_CR51","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942\u201354.","journal-title":"Br J Dermatol"},{"key":"1538_CR52","unstructured":"Bimzelx | European Medicines Agency (EMA) [Internet]. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx. Accessed 5 Mar 2025."},{"issue":"12","key":"1538_CR53","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/jdv.12046","volume":"27","author":"AB Kimball","year":"2013","unstructured":"Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535\u201345.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9625","key":"1538_CR54","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384.","journal-title":"Lancet"},{"key":"1538_CR55","unstructured":"Ilumetri | European Medicines Agency (EMA) [Internet]. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_en.pdf. Accessed 17 July 2025."},{"issue":"10091","key":"1538_CR56","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"3","key":"1538_CR57","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605\u201317.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1538_CR58","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/09546634.2019.1640348","volume":"31","author":"B Elewski","year":"2020","unstructured":"Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, et al. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatol Treat. 2020;31(8):763\u20138.","journal-title":"J Dermatol Treat"},{"issue":"9","key":"1538_CR59","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s13555-022-00789-9","volume":"12","author":"G Kokolakis","year":"2022","unstructured":"Kokolakis G, Kreis G, Falqu\u00e9s M, Aparici M, Sondermann W. High tolerability, favorable safety, and subjects\u2019 preference for a single 200 mg\/2 ml tildrakizumab injection: a phase I, open-label, randomized crossover trial in healthy volunteers. Dermatol Ther (Heidelb). 2022;12(9):2135\u201344.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1538_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2438803","volume":"36","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Tha\u00e7i D. Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe. J Dermatol Treat. 2025;36(1):2438803.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1538_CR61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","volume":"22","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Chiricozzi A, Cinotti E, Brunasso G, Congedo M, Esposito M, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opin Biol Ther. 2022;22(3):367\u201376.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1538_CR62","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jdv.18167","volume":"36","author":"AP Fernandez","year":"2022","unstructured":"Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol. 2022;36(10):1774\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1538_CR63","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jdv.15400","volume":"33","author":"KA Papp","year":"2019","unstructured":"Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatol Venereol. 2019;33(6):1098\u2013106.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1538_CR64","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the resurface pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1538_CR65","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.19229","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G, Cuccia A, Rivera-Diaz R, Gaarn Du Jardin K, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004\u201315.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1538_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.263","volume":"3","author":"J Griss","year":"2023","unstructured":"Griss J, Ratzinger G, Maul JT, Weger W, Tha\u00e7i D, Carrascosa JM, et al. No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies. Skin Health Dis. 2023;3(5):e263.","journal-title":"Skin Health Dis"},{"issue":"12","key":"1538_CR67","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","volume":"33","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(12):2305\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1538_CR68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ad.2023.08.019","volume":"115","author":"FJ Melgosa Ramos","year":"2024","unstructured":"Melgosa Ramos FJ, Mateu Puchades A, Mat\u00e1ix-D\u00edaz J, Schneller-Pavelescu L, Belinch\u00f3n-Romero I, Santos Alarc\u00f3n S. 52-week mid-term efficacy of Tildrakizumab in moderate-to-severe psoriasis: a real-life multicenter experience. Actas Dermo-Sifiliogr. 2024;115(7):722\u20136.","journal-title":"Actas Dermo-Sifiliogr"},{"key":"1538_CR69","volume":"10","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2021\u20132\u20136.","journal-title":"Drugs Context"},{"issue":"2","key":"1538_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/24755303221077211","volume":"7","author":"NW Wei","year":"2022","unstructured":"Wei NW, Chi S, Lebwohl MG. Retrospective analysis in patients with moderate to severe plaque psoriasis treated with tildrakizumab: real-life clinical data. J Psoriasis Psoriatic Arthritis. 2022;7(2):55\u20139.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"11","key":"1538_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15818","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Cariti C, Susca S, Sciamarrelli N, Borriello S, Ortoncelli M, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35(11):e15818.","journal-title":"Dermatol Ther"},{"issue":"18","key":"1538_CR72","first-page":"6772","volume":"26","author":"M Burlando","year":"2022","unstructured":"Burlando M, Maul JT, Salvi I, Simic D, Cozzani E, Ak M, et al. Psoriasis patients\u2019 characteristics associated with high PASI response to tildrakizumab: an international dual center study. Eur Rev Med Pharmacol Sci. 2022;26(18):6772\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"1538_CR73","doi-asserted-by":"publisher","first-page":"e803","DOI":"10.1111\/jdv.16648","volume":"34","author":"MA Menter","year":"2020","unstructured":"Menter MA, Murakawa GJ, Glover H, Mendelsohn AM, Parno J, Rozzo SJ, et al. Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. J Eur Acad Dermatol Venereol. 2020;34(12):e803\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1538_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092631","volume":"11","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, Tofani L, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631.","journal-title":"J Clin Med"},{"issue":"1","key":"1538_CR75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"1538_CR76","first-page":"03393","volume":"S0190\u20139622","author":"HL Sofen","year":"2024","unstructured":"Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;S0190\u20139622(24):03393.","journal-title":"J Am Acad Dermatol"},{"key":"1538_CR77","doi-asserted-by":"publisher","first-page":"adv17752","DOI":"10.2340\/actadv.v103.17752","volume":"103","author":"ELM Ter Haar","year":"2023","unstructured":"Ter Haar ELM, Van den Reek JMPA, Gaarn Du Jardin K, Barbero-Castillo A, De Jong EMGJ, Lubeek SFK. Efficacy and safety of tildrakizumab in older patients: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 244 weeks. Acta Derm Venereol. 2023;103:adv17752.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1538_CR78","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14712598.2024.2325547","volume":"24","author":"P Dapavo","year":"2024","unstructured":"Dapavo P, Burlando M, Guarneri C, Megna M, Narcisi A, Talamonti M, et al. Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden. Expert Opin Biol Ther. 2024;24(3):133\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1538_CR79","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s13555-022-00800-3","volume":"12","author":"G Becher","year":"2022","unstructured":"Becher G, Conner S, Ingram JA, Stephen KE, McInnes AC, Heald AH, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343\u201354.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1538_CR80","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2350760","volume":"35","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoruso F, Balato A, et al. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis). J Dermatol Treat. 2024;35(1):2350760.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1538_CR81","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1404a284","volume":"14","author":"EV Di Brizzi","year":"2024","unstructured":"Di Brizzi EV, Caccavale S, Di Caprio R, Cusano F, De Pasquale R, Falcomat\u00e0 V, et al. A prospective real-life multicenter study of tildrakizumab 200 mg in patients with moderate-severe psoriasis: who is the ideal patient? Dermatol Pract Concept. 2024;14(4):e2024284.","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"1538_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2420825","volume":"35","author":"A Dattola","year":"2024","unstructured":"Dattola A, Bernardini N, Svara F, Balato A, Caldarola G, D\u2019Amico D, et al. Effectiveness of tildrakizumab 200 mg: an Italian multicenter study. J Dermatol Treat. 2024;35(1):2420825.","journal-title":"J Dermatol Treat"},{"key":"1538_CR83","volume":"17","author":"P Dapavo","year":"2024","unstructured":"Dapavo P, Megna M, Talamonti M. Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis. Dermatol Rep. 2024;17:9999.","journal-title":"Dermatol Rep"},{"issue":"1","key":"1538_CR84","first-page":"70","volume":"160","author":"E Trovato","year":"2025","unstructured":"Trovato E, Dragotto M, Capalbo E, Lamberti A, Rubegni P. Facial psoriasis treated with tildrakizumab. Ital J Dermatol Venerol. 2025;160(1):70\u20131.","journal-title":"Ital J Dermatol Venerol"},{"issue":"6","key":"1538_CR85","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s13555-025-01416-z","volume":"15","author":"M Valenti","year":"2025","unstructured":"Valenti M, Ibba L, Di Giulio S, Gargiulo L, Malagoli P, Balato A, et al. Optimizing tildrakizumab dosing in psoriasis: a 52-week multicenter retrospective study comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb). 2025;15(6):1427-40.\u00a0","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"17","key":"1538_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175240","volume":"13","author":"E Trovato","year":"2024","unstructured":"Trovato E, Dragotto M, Capalbo E, Cartocci A, Rubegni P, Calabrese L. Uncovering the differences: how DLQI and WHO-5 scores vary in moderate-to-severe psoriasis patients treated with tildrakizumab 100 mg versus. 200 mg? J Clin Med. 2024;13(17):5240.","journal-title":"J Clin Med"},{"issue":"2","key":"1538_CR87","first-page":"10140","volume":"17","author":"V Lora","year":"2025","unstructured":"Lora V, Graceffa D, Di Prete M, Cota C. Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs. Dermatol Rep. 2025;17(2):10140.","journal-title":"Dermatol Rep"},{"issue":"2","key":"1538_CR88","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5414\/CP202176","volume":"53","author":"A Zandvliet","year":"2015","unstructured":"Zandvliet A, Glasgow S, Horowitz A, Montgomery D, Marjason J, Mehta A, et al. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther. 2015;53(2):139\u201346.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"1538_CR89","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16724","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615\u201322.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1538_CR90","doi-asserted-by":"publisher","first-page":"e709","DOI":"10.1111\/jdv.17427","volume":"35","author":"D Tha\u00e7i","year":"2021","unstructured":"Tha\u00e7i D, Jullien D, Egeberg A, Carrascosa JM, Wu JJ, Pau-Charles I, et al. Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. J Eur Acad Dermatol Venereol. 2021;35(11):e709\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1538_CR91","first-page":"243","volume":"15","author":"U Mrowietz","year":"2025","unstructured":"Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daud\u00e9n E, et al. Patient-reported well-being in value-based routine care using tildrakizumab: 52-week interim data of the phase IV positive study. Psoriasis (Auckland). 2025;15:243\u201359.","journal-title":"Psoriasis (Auckland)"},{"issue":"6","key":"1538_CR92","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/bjd.21827","volume":"187","author":"U Mrowietz","year":"2022","unstructured":"Mrowietz U, Augustin M. Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people-centred healthcare concept of the World Health Organization. Br J Dermatol. 2022;187(6):1007\u20138.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1538_CR93","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s13555-024-01257-2","volume":"14","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, McLean RR, Beaty SW, Sima AP, Low R, Stark JL, et al. Impact of disease burden of patients with psoriasis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2024;14(10):2787\u2013804.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1538_CR94","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","volume":"182","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020;182(6):1359\u201368.","journal-title":"Br J Dermatol"},{"key":"1538_CR95","unstructured":"Enbrel | European Medicines Agency (EMA) [Internet]. 2009. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enbrel. Accessed 5 Mar 2025."},{"key":"1538_CR96","unstructured":"Humira | European Medicines Agency (EMA) [Internet]. 2009. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira. Accessed 5 Mar 2025."},{"key":"1538_CR97","unstructured":"Cimzia | European Medicines Agency (EMA) [Internet]. 2009. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cimzia. Accessed 5 Mar 2025."},{"key":"1538_CR98","unstructured":"Cosentyx | European Medicines Agency (EMA) [Internet]. 2015. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx. Accessed 5 Mar 2025."},{"key":"1538_CR99","unstructured":"Stelara | European Medicines Agency (EMA) [Internet]. 2009. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara. Accessed 5 Mar 2025."},{"issue":"7","key":"1538_CR100","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s13555-025-01442-x","volume":"15","author":"E Trovato","year":"2025","unstructured":"Trovato E, Bianchelli T, Odorici G, Cuccia A, Di Lernia VG, Lasagni C, et al. Effectiveness of tildrakizumab 200 mg in moderate-to-severe plaque psoriasis: a multicenter real-world study analyzing patient outcomes by weight, PASI, BMI, and previous therapies. Dermatol Ther (Heidelb). 2025;15(7):1941\u201352.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1538_CR101","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2512159","volume":"36","author":"C Lanna","year":"2025","unstructured":"Lanna C, Rivieccio A, Cattani C, Artosi F, Bianchi L, Campione E. Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits. J Dermatol Treat. 2025;36(1):2512159.","journal-title":"J Dermatol Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01538-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01538-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01538-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:02:42Z","timestamp":1761242562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01538-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01538-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ricardo Ruiz-Villaverde declares that he has received funding for attendance at meetings and conferences, speaker fees and funding for participating in research from Almirall, Sunpharma, Celgene, Leo-Pahrma, Sanofi, Abbvie, Lilly, Novartis, Galderma, Pfizer, UCB Pharma and Janssen. Almudena Mateu has potential conflict of interests (advisory board member, consultant, research support, participation in clinical trials and honorary for speaking) with the following pharmaceutical companies AbbVie, Almirall SA, Celgene, Jansen-Cilag, Leo-Pharma, Lilly, Novartis and Pfizer. Pedro Mendes-Bastos has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by Lilly, AbbVie, Alumis, Johnson & Johnsson Innovative Medicine, Novartis, LEO Pharma, Almirall, Sanofi, Regeneron, Viatris, Pierre Fabre, L\u2019Or\u00e9al, Organon, Evelo Biosciences, CS Portugal, Pfizer, Biogen, Apogee Therapeutics and Amgen. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA and UCB. Tiago Torres is an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}